Skip to content

Study · Non-randomized trial · n = 18 · 1994

11 results

Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity.

Kirk JM, Trainer PJ, Majrowski WH, Murphy J, Savage MO, Besser GM

Clinical endocrinology1 Oct 1994Cited by 11 (Europe PMC)

PMID7955460 (opens in a new tab)DOI10.1111/j.1365-2265.1994.tb02580.x (opens in a new tab)PepBankPUB-07955460
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In pre-pubertal children with idiopathic short stature, GHRH(1-29)NH2 raised mean height velocity from 4.8 to 7.2 cm/year after 12 months.

    In plain wordsIn short children without GH deficiency, GHRH(1-29)NH2 raised growth speed over 12 months.

    Peptide
    Sermorelin
    Outcome
    IncreaseHeight velocity after 12 months
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Height velocity
    7.2 cm/year
    after 12 months

    Source sentences

    Summary
    Mean (SD) height velocity (HV) increased from 4.8(0.9)cm/year pre-treatment to 7.2(1.6)cm/year after 12 months of therapy (P = 0.001).
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  2. 02HumanNon-randomized trialEfficacy outcome

    Children who grew slowly before treatment had a greater growth response than those who grew normally.

    In plain wordsChildren who grew slowly before treatment responded more than children who grew normally.

    Peptide
    Sermorelin
    Outcome
    Not applicableHeight velocity response by pretreatment growth rate
    Study

    n = 18

    Comparator
    Children growing normally before treatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The children growing slowly (HV or = 25th centile) before treatment.
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  3. 03HumanNon-randomized trialEfficacy outcome

    Final height prediction increased by a mean of 3.4 cm during GHRH(1-29)NH2 treatment.

    In plain wordsPredicted final height went up by a mean of 3.4 cm during treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseFinal height prediction
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Final height prediction change
    3.4 cm

    Source sentences

    Summary
    Final height prediction increased by a mean (SD) of 3.4(2.6)cm.
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  4. 04HumanNon-randomized trialActivity measurement

    Overnight GH levels fell during 12 months of GHRH(1-29)NH2 therapy.

    In plain wordsOvernight GH levels fell during 12 months of treatment.

    Peptide
    Sermorelin
    Outcome
    DecreaseOvernight GH levels
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Overnight GH levels
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  5. 05HumanNon-randomized trialActivity measurement

    GH responses to GHRH testing fell during 12 months of GHRH(1-29)NH2 therapy.

    In plain wordsGH responses to a GHRH test fell during 12 months of treatment.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH response to GHRH testing
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    GH responses to GHRH testing fell during the 12 months of therapy.
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  6. 06HumanNon-randomized trialSafety outcome

    Fasting blood glucose increased during GHRH(1-29)NH2 therapy.

    In plain wordsFasting blood glucose rose during treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseFasting blood glucose
    Study

    n = 18

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Fasting blood glucose and insulin levels increased during therapy
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  7. 07HumanNon-randomized trialSafety outcome

    Fasting insulin levels increased during GHRH(1-29)NH2 therapy.

    In plain wordsFasting insulin levels rose during treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseFasting insulin
    Study

    n = 18

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Fasting blood glucose and insulin levels increased during therapy
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  8. 08HumanNon-randomized trialEfficacy outcome

    IGF-I levels increased during GHRH(1-29)NH2 therapy.

    In plain wordsIGF-I levels rose during treatment.

    Peptide
    Sermorelin
    Outcome
    IncreaseIGF-I
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    as did IGF-I.
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  9. 09HumanNon-randomized trialOther

    One child was non-compliant and was withdrawn before 3 months of GHRH(1-29)NH2 therapy.

    In plain wordsOne child did not follow the treatment plan and left the study before 3 months.

    Peptide
    Sermorelin
    Outcome
    Not applicableWithdrawal for non-compliance
    Study

    n = 18

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    One patient was non-compliant and was withdrawn prior to 3 months of therapy.
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  10. 10HumanNon-randomized trialEfficacy outcome

    After GHRH(1-29)NH2 was stopped, height velocity fell to 3.89 cm/year during the first 3 months off therapy (catch-down growth).

    In plain wordsAfter treatment stopped, growth speed dropped in the first 3 months.

    Peptide
    Sermorelin
    Outcome
    DecreaseHeight velocity in first 3 months off therapy
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Height velocity
    3.89 cm/year
    first 3 months off therapy

    Source sentences

    Summary
    Cessation of GHRHa was followed by catch-down growth during the first 3 months off therapy: mean (SD) HV 3.89(1.82)cm/year (P < 0.04)
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.
  11. 11HumanNon-randomized trialEfficacy outcome

    Height velocity at 6 and 12 months after stopping GHRH(1-29)NH2 was not different from pretreatment values.

    In plain wordsSix and 12 months after treatment stopped, growth speed was back to its level before treatment.

    Peptide
    Sermorelin
    Outcome
    No significant changeHeight velocity 6 and 12 months off therapy
    Study

    n = 18

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    20 micrograms/kg twice daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    although the HV after 6 months (4.9(1.0))cm/year) and 12 months (4.4(1.0)cm/year) was not different from pretreatment values.
    1 context sentence
    Summary · context
    Eighteen short pre-pubertal children (aged 4.3-11.0 years, 17 male) with idiopathic short stature (height 20 mU/l) were recruited to receive GHRHa 20 micrograms/kg by twice daily s.c. injection for one year.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.